MedTrace Logo

Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

NCT05677334 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-03-12

No results posted yet for this study

Summary

The Multi-center, randomized, controlled clinical trial investigate the efficacy and safety of Henagliflozin combined with continuous subcutaneous insulin infusion in newly diagnosed type 2 diabetes

Conditions

  • Type2diabetes

Interventions

DRUG

Henagliflozin

Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion

DEVICE

Continuous Subcutaneous Insulin Infusion

Continuous Subcutaneous Insulin Infusion therapy alone

Sponsors & Collaborators

  • First Affiliated Hospital of Guangxi Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-10-30
Completion
2024-10-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05677334 on ClinicalTrials.gov